Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

Safety Issues Clinical Trial

Official title:

A Prospective Intervention Phase I Study in Three Age De-escalating Group to Assess the Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03462108
• Other study ID #: RV 0117
• Status: Completed
• Phase: Phase 1
• Start date: April 9, 2018
• Est. completion date: March 30, 2019

Study information

• Verified date: April 2018
• Source: PT Bio Farma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to assess the safety of Rotavirus (Bio Farma) vaccine in adults, children and neonates.

Description:

To describe the safety of this vaccine after each immunization. To assess preliminary information of immunogenicity following Rotavirus (Bio Farma) vaccine immunization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: March 30, 2019
• Est. primary completion date: February 18, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 40 Years

Eligibility

Inclusion Criteria for Adults:

• Healthy Adults as determined by clinical judgment, including a medical history, physical exam and laboratory results, which confirms the absence of a current or past disease state considered significant by the investigator.

• Subjects have been informed properly regarding the study and signed the informed consent form.

• Subject will commit to comply with the instructions of the investigator and the schedule of the trial.

Inclusion Criteria for Children:

• Healthy Children as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.

• Parents/guardian(s) have been informed properly regarding the study and signed the informed consent form

• Parent/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.

Inclusion Criteria for Neonates:

• Neonate 0-5 days of age at the time of first dose, with cord blood available

• Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.

• The neonate was born full term (minimum of 36 completed weeks and maximum of 42 completed weeks gestation).

• Neonate birth weight 2500-4000 g inclusive.

• Parents or guardians have been informed properly regarding the study and signed the informed consent form

• Parents or guardians will commit to comply with the instructions of the investigator and the schedule of the trial

Exclusion Criteria for Adults:

• Subject concomitantly enrolled or scheduled to be enrolled in another trial

• Any direct relatives relationship with the study team.

• Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.

• Known history of allergy to any component of the vaccines

• Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy)

• Gastroenteritis in the 24 hours preceding enrollment.

• History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.

• Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or corticosteroid therapy and other immunosuppresant).

• Subject consuming or expect to consume a probiotics within one week before and after vaccination

• Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.

• Pregnancy & lactation (Adults).

• Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.

• Subject planning to move from the study area before the end of study period.

Exclusion Criteria for Children:

• Subject concomitantly enrolled or scheduled to be enrolled in another trial

• Any direct relatives relationship with the study team

• Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C ) within the 48 hours preceding enrollment

• Known history of allergy to any component of the vaccines

• Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy)

• Gastroenteritis in the 24 hours preceding enrollment.

• Any clinically significant history of chronic gastrointestinal disease including uncorrected congenital malformation of gastrointestinal tract that would predispose for Intusussception.

• History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.

• Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or corticosteroid therapy and other immunosuppresant).

• Subjects consuming or expect to consume a probiotics within one week before and after vaccination.

• Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.

• Individuals who have previously received any rotavirus vaccine.

• Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.

• Subject planning to move from the study area before the end of study period

Exclusion Criteria for Neonates:

• Subject concomitantly enrolled or scheduled to be enrolled in another trial.

• Any direct relatives relationship with the study team.

• Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.

• Subject with known or suspected history of allergy to any component of the vaccines.

• Subject with a biological mother with a known or suspected human immunodeficiency virus (HIV) infection.

• Subject with known or suspected major congenital malformations or genetically determined disease.

• Subject with intussusception.

• Subject with a known or suspected disease of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.

• Subject with a known or suspected disease of the immune system or those who has received immunosuppresive therapy, including immunosuppresive courses of systemic corticosteroid.

• Subject who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product during the course of study.

• Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.

• Subject immunized with non- EPI vaccines.

• Gastroenteritis in the 24 hours preceding enrollment.

• Subject planning to move from the study area before the end of study period.

Related Conditions & MeSH terms

• Safety Issues

Intervention

Biological:
• Rotavirus (Bio Farma) Vaccine
Rotavirus (Bio Farma) Vaccine

Other:
• Placebo
Placebo contains 30% sucrose in DMEM

Locations

Country	Name	City	State
Indonesia	Gantiwarno Primary Health Center	Klaten	Central Java
Indonesia	Klaten Selatan Primary Health Center	Klaten	Central Java
Indonesia	Ngawen Primary Health Center	Klaten	Central Java
Indonesia	RS Soeradji Tritonegoro	Klaten	Central Java

Sponsors (1)

Lead Sponsor	Collaborator
PT Bio Farma

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Solicited symptoms after each immunization	Number of subjects with solicited systemic and gastrointestinal symptoms in the day 0-7 following each dose of investigational product	0-7 days
Secondary	Adverse events of Rotavirus (Bio Farma) vaccine	Number and percentage of subjects with unsolicited Adverse Events (AE) in the day 0-28 following each dose of investigational product	28 days
Secondary	Serious adverse events of Rotavirus (Bio Farma) vaccine	Number and percentage of subjects with Serious Adverse Events (SAE) within 28 days after each dose of investigational product	28 days
Secondary	Adverse events of Rotavirus (Bio Farma) vaccine compare to placebo in neonates group	Number and percentage of subject with adverse event (AE) within 28 days after each dose of investigational product compare to placebo (in neonates group)	28 days
Secondary	Serious adverse events of Rotavirus (Bio Farma) vaccine compare to placebo in neonates group	Number and percentage of subject with Serious Adverse Events (SAE) within 28 days after each dose of investigational product compare to placebo (in neonates group)	28 days
Secondary	Number of subject who has abnormality value of routine hematology and biochemical evaluation that probably related to the vaccination	Deviation in routine hematology and biochemical evaluation	7 days
Secondary	Excretion of rotavirus in stools in neonates group	Number of neonates with rotavirus excretion in stools	3-7 days
Secondary	Number of subjects with >=3 times increasing antibody from baseline to post investigational product dosing	Subjects with >=3 times increasing antibody from baseline to post investigational product dosing	4-6 weeks after last immunization
Secondary	Serum anti-rotavirus immunoglobulin (Ig)A following immunization	Serum anti-rotavirus immunoglobulin (Ig)A before and after last immunization	4-6 weeks after last immunization
Secondary	Serum neutralizing antibody (SNA) following immunization	Serum neutralizing antibody (SNA) before and after last immunization	4-6 weeks after last immunization
Secondary	Geometric Mean Titer (GMT) following immunization	Geometric mean titer (GMT) before and after last immunization	4-6 weeks after last immunization